Skip to content
Clinical Trials – home
Viiv Healthcare UK Limited
Sponsor

Viiv Healthcare UK Limited

United Kingdom 79 New Oxford Street, WC1A 1DG, United Kingdom

About the sponsor

Clinical research includes oral and long-acting antiretroviral therapy options for adults newly diagnosed with HIV, with attention to viral suppression, treatment initiation, and regimen selection in people who have not previously received therapy.

  • Oral once-daily treatment regimens
  • Long-acting injectable ART
  • Viral suppression in treatment-naïve adults

Studies also examine comparative effectiveness between simplified dual-drug and standard multi-drug approaches in initial HIV-1 management.

About Specializations

Viiv Healthcare UK Limited runs clinical trials in conditions such as HIV infection, among others.

Recruiting now

Ongoing trials

Clinical trials run by this sponsor – those enrolling participants first.

Condition
Country
City
Type of trial
Recruitment status
Quick filters

11 clinical trials

HIV infection

Recruiting

Cabotegravir and Rilpivirine Ultra‑Long‑Acting vs Long‑Acting in Adults and Adolescents with HIV Who Are Virally Suppressed

Registered drugNo placebo
Countries:SpainSpain
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Cabotegravir
  • Sponsor:Viiv Healthcare UK Limited

HIV infection

Recruiting

A study testing VH4524184 with emtricitabine and tenofovir alafenamide compared to dolutegravir and lamivudine in adults with HIV-1 who have not received treatment before

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Dolutegravir Sodium
  • Sponsor:Viiv Healthcare UK Limited

HIV infection

Not yet recruiting

Study of Fostemsavir in Adults with HIV Transitioning from Prior ViiV Clinical Trials for Continued Treatment Access

Registered drugNo placebo
Countries:RomaniaRomania
  • Participants:18–64 years · 65+ years
  • Substances:Fostemsavir
  • Sponsor:Viiv Healthcare UK Limited

HIV infection

Not recruiting

Study on the Effectiveness of Cabotegravir and Rilpivirine for People with HIV-1 Who Have Not Responded Well to Oral Treatment

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Cabotegravir
  • Sponsor:Viiv Healthcare UK Limited

HIV infection

Not recruiting

Study on the Safety and Effectiveness of Fostemsavir for Patients with Multi-drug Resistant HIV-1 Who Have Had Extensive Previous Treatments

Registered drugNo placebo
Countries:RomaniaRomania
  • Participants:18–64 years · 65+ years
  • Substances:Fostemsavir
  • Sponsor:Viiv Healthcare UK Limited

HIV infection

Not recruiting

Study on the Effects of VH4524184 for Adults Newly Diagnosed with HIV

Investigational
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:VH4524184
  • Sponsor:Viiv Healthcare UK Limited

HIV infection

Not recruiting

Study on Switching HIV Treatment to Dolutegravir/Lamivudine in Patients Aged 50+ with Virologic Suppression

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Bictegravir
  • Sponsor:Viiv Healthcare UK Limited

HIV infection

Not recruiting

Study on the Effectiveness and Safety of Lamivudine, Dolutegravir Sodium, Cabotegravir, and Rilpivirine for Adults with HIV-1 Who Have Not Taken Antiretroviral Therapy

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Cabotegravir
  • Sponsor:Viiv Healthcare UK Limited

HIV infection

Not recruiting

Study on the Effects of GSK4004280 and GSK4011499 in Adults with HIV Infections

Investigational
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:GSK4004280
  • Sponsor:Viiv Healthcare UK Limited

HIV infection

Not recruiting

Study on the Effects of GSK3739937 for Adults with HIV-1 Who Have Not Yet Received Treatment

Investigational
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:GSK3739937
  • Sponsor:Viiv Healthcare UK Limited

HIV infection

Not recruiting

Study Comparing Dolutegravir/Lamivudine to Bictegravir/Emtricitabine/Tenofovir Alafenamide for HIV Treatment in Adults New to Antiretroviral Therapy

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Bictegravir
  • Sponsor:Viiv Healthcare UK Limited

Are you running a clinical trial?

Increase visibility for your trials and help patients find your site through our platform.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.